James Ford

Publications

• Molecular profiling of gastric cancer: toward personalized cancer medicine. Nadauld LD, Ford JM. J Clin Oncol. 2013; 31 (7): 838-9
• Genetic testing by cancer site: stomach. Chun N, Ford JM. Cancer J. 2012 Jul-Aug; 18 (4): 355-63
• Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomol. Alli E, Ford JM. DNA Repair (Amst). 2012; 11 (5): 522-4
• Is breast cancer a part of Lynch syndrome? Ford JM, Breast Cancer Res. 2012; 14 (4): 110
• Long-term survivors of gastric cancer: a California population-based study. Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. J Clin Oncol. 2012; 30 (28): 3507-15
• Lupus antibody tops cancer cells. Ford JM, Sci Transl Med. 2012; 4 (157): 157fs38
• Lynch syndrome in patients with colorectal cancer: finding the needle in the haystack. Ladabaum U, Ford JM. JAMA. 2012; 308 (15): 1581-3
• Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. Alli E, Sharma VB, Hartman AR, Lin PS, McPherson L, Ford JM. BMC Pharmacol. 2011: 11 7
• Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA. Ann Intern Med. 2011; 155 (2): 69-79
• Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Hastak K, Alli E, Ford JM. Cancer Res. 2010; 70 (20): 7970-80
• Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Alli E, Sharma VB, Sunderesakumar P, Ford JM. Cancer Res. 2009; 69 (8): 3589-96
• Second primary breast cancer occurrence according to hormone receptor status. Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. J Natl Cancer Inst. 2009; 101 (15): 1058-65
• Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. Cisco RM, Ford JM, Norton JA. Cancer. 2008; 113 (7 Suppl): 1850-6
• Performance of BRCA1/2 mutation prediction models in Asian Americans. Kurian AW, Gong GD, Chun NM, Mills MA, Staton AD, Kingham KE, Crawford BB, Lee R, Chan S, Donlon SS, Ridge Y, Panabaker K, West DW, Whittemore AS, Ford JM. J Clin Oncol. 2008; 26 (29): 4752-8
• CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG, Chun N, Kurian AW, Ford JM. Ann Surg. 2007; 245 (6): 873-9
• Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinoma. Ji H, Kumm J, Zhang M, Farnam K, Salari K, Faham M, Ford JM, Davis RW. Cancer Res. 2006; 66 (16): 7910-9
• Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase eta on ATR checkpoint signaling. Bomgarden RD, Lupardus PJ, Soni DV, Yee MC, Ford JM, Cimprich KA. EMBO J. 2006; 25 (11): 2605-14
• Predicting and preventing hereditary colorectal cancer. Ford JM, Whittemore AS. JAMA. 2006; 296 (12): 1521-3
• In vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product. Fitch ME, Nakajima S, Yasui A, Ford JM. J Biol Chem. 2003; 278 (47): 46906-10
• The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. Fitch ME, Cross IV, Turner SJ, Adimoolam S, Lin CX, Williams KG, Ford JM. DNA Repair (Amst). 2003; 2 (7): 819-26
• p53 and regulation of DNA damage recognition during nucleotide excision repair. Adimoolam S, Ford JM. DNA Repair (Amst). 2003; 2 (9): 947-54
• p53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo. Fitch ME, Cross IV, Ford JM. Carcinogenesis. 2003; 24 (5): 843-50
• BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Hartman AR, Ford JM. Nat Genet. 2002; 32 (1): 180-4
• p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Adimoolam S, Ford JM. Proc Natl Acad Sci U S A. 2002; 99 (20): 12985-90
• Xeroderma pigmentosum p48 gene enhances global genomic repair and suppresses UV-induced mutagenesis. Tang JY, Hwang BJ, Ford JM, Hanawalt PC, Chu G. Mol Cell. 2000; 5 (4): 737-44
• Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Hwang BJ, Ford JM, Hanawalt PC, Chu G. Proc Natl Acad Sci U S A. 1999; 96 (2): 424-8
• Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. Ford JM, Hanawalt PC. J Biol Chem. 1997; 272 (44): 28073-80
• Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Ford JM, Hanawalt PC. Proc Natl Acad Sci U S A. 1995; 92 (19): 8876-80
• A young woman with bilateral breast cancer: identifying a genetic cause and implications for management. de Bruin MA, Ford JM, Kurian AW. J Natl Compr Canc Netw. 2013; 11 (5): 512-7
• Seventh edition (2010) of the AJCC/UICC staging system for gastric adenocarcinoma: is there room for improvement? Patel MI, Rhoads KF, Ma Y, Ford JM, Visser BC, Kunz PL, Fisher GA, Chang DT, Koong A, Norton JA, Poultsides GA. Ann Surg Oncol. 2013; 20 (5): 1631-8
• Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. de Bruin MA, Kwong A, Goldstein BA, Lipson JA, Ikeda DM, McPherson L, Sharma B, Kardashian A, Schackmann E, Kingham KE, Mills MA, West DW, Ford JM, Kurian AW. Fam Cancer. 2012; 11 (3): 429-39
• Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome. Henry E, Villalobos V, Million L, Jensen KC, West R, Ganjoo K, Lebensohn A, Ford JM, Telli ML. J Natl Compr Canc Netw. 2012; 10 (8): 939-42
• Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, Koong AC, Kunz PA, Fisher GA, Ford JM, Welton M, Shelton A, Ma L, Arber DA, Pai RK. Mod Pathol. 2012; 25 (8): 1128-39
• Family history as a positive prognostic factor in gastric cancer. Nadauld LD, Ford JM. J Clin Oncol. 2012; 30 (7): 683-4
• HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. Appl Immunohistochem Mol Morphol. 2012; 20 (1): 13-24
• Identification of a Functional In Vivo p53 Response Element in the Coding Sequence of the Xeroderma Pigmentosum Group C Gene. Hastak K, Adimoolam S, Trinklein ND, Myers RM, Ford JM. Genes Cancer. 2012; 3 (2): 131-40
• Identification of a novel deletion mutant strain in Saccharomyces cerevisiae that results in a microsatellite instability phenotype. Ji HP, Morales S, Welch K, Yuen C, Farnam K, Ford JM. Biodiscovery. 2012; (1)
• Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Abelson JA, Murphy JD, Minn AY, Chung M, Fisher GA, Ford JM, Kunz P, Norton JA, Visser BC, Poultsides GA, Koong AC, Chang DT. Int J Radiat Oncol Biol Phys. 2012; 82 (4): e595-601
• Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH, Davis RW, Jeffrey SS. PLoS One. 2012; 7 (5): e33788
• A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Chen Y, Kingham K, Ford JM, Rosing J, Van Dam J, Jeffrey RB, Longacre TA, Chun N, Kurian A, Norton JA. Ann Surg Oncol. 2011; 18 (9): 2594-8
• A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mojtahed A, Schrijver I, Ford JM, Longacre TA, Pai RK. Mod Pathol. 2011; 24 (7): 1004-14
• Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Telli ML, Chang ET, Kurian AW, Keegan TH, McClure LA, Lichtensztajn D, Ford JM, Gomez SL. Breast Cancer Res Treat. 2011; 127 (2): 471-8
• Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, Welton ML, Shelton A, Kapp DS, Koong AC, Goodman KA, Chang DT. Cancer. 2011; 117 (15): 3342-51
• Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Minn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, Chang DT. Cancer. 2010; 116 (16): 3943-52
• Expression of p16(INK4A) but not hypoxia markers or poly adenosine diphosphate-ribose polymerase is associated with improved survival in patients with pancreatic adenocarcinoma. Chang DT, Chapman CH, Norton JA, Visser B, Fisher GA, Kunz P, Ford JM, Koong AC, Pai RK. Cancer. 2010; 116 (22): 5179-87
• Hereditary diffuse gastric cancer due to a previously undescribed CDH1 splice site mutation. Matsukuma KE, Mullins FM, Dietz L, Zehnder JL, Ford JM, Chun NM, Schrijver I. Hum Pathol. 2010; 41 (8): 1200-3
• Longer relative telomere length in blood from women with sporadic and familial breast cancer compared with healthy controls. Gramatges MM, Telli ML, Balise R, Ford JM. Cancer Epidemiol Biomarkers Prev. 2010; 19 (2): 605-13
• Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. La TH, Minn AY, Su Z, Fisher GA, Ford JM, Kunz P, Goodman KA, Koong AC, Chang DT. Dis Esophagus. 2010; 23 (4): 300-8
• Novel treatment approaches for triple-negative breast cancer. Telli ML, Ford JM. Clin Breast Cancer. 2010: 10 Suppl 1 E16-22
• Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD. Cancer Res. 2010; 70 (2): 512-9
• PARP Inhibitors for the Treatment and Prevention of Breast Cancer. Vinayak S, Ford JM. Curr Breast Cancer Rep. 2010; 2 (4): 190-197
• PARP inhibitors in breast cancer. Telli ML, Ford JM. Clin Adv Hematol Oncol. 2010; 8 (9): 629-35
• Pathological response after chemoradiation for T3 rectal cancer. Chennupati SK, Kamaya A, Fisher GA, Ford JM, Kunz P, Itakura H, Welton ML, Shelton A, Van Dam J, Koong AC, Chang DT. Colorectal Dis. 2010; 12 (7 Online): e24-30
• Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA. Clin Cancer Res. 2010; 16 (19): 4702-10
• A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Kwong A, Wong LP, Wong HN, Law FB, Ng EK, Tang YH, Chan WK, Ho LS, Kwan KH, Poon M, Wong TT, Leung FC, Chan SW, Ying MW, Ma ES, Ford JM. Breast Cancer Res Treat. 2009; 117 (3): 683-6
• Detection of solitary humeral metastasis from pancreatic adenocarcinoma with F-18 FDG PET/CT. Kim J, Quon A, Humke E, Ford JM, Koong AC. Clin Nucl Med. 2009; 34 (5): 312-3
• Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, Fisher GA, Le QT, Chang DT, Ji H, Koong AC. J Transl Med. 2009: 7 105
• Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC. Cancer. 2009; 115 (3): 665-72
• The role of the retinoblastoma/E2F1 tumor suppressor pathway in the lesion recognition step of nucleotide excision repair. Lin PS, McPherson LA, Chen AY, Sage J, Ford JM. DNA Repair (Amst). 2009; 8 (7): 795-802
• Magnetic resonance galactography: a feasibility study in women with prior atypical breast duct cytology. Kurian AW, Hartman AR, Mills MA, Logan LJ, Sawyer AM, Ford JM, Daniel BL. Breast J. 2008 Mar-Apr; 14 (2): 211-4
• Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Staton AD, Kurian AW, Cobb K, Mills MA, Ford JM. Fam Cancer. 2008; 7 (2): 179-86
• Characterization of the pathogenic mechanism of a novel BRCA2 variant in a Chinese family. Kwong A, Wong LP, Chan KY, Ma ES, Khoo US, Ford JM. Fam Cancer. 2008; 7 (2): 125-33
• Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP, Koong AC. Int J Radiat Oncol Biol Phys. 2008; 72 (3): 678-86
• Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family. Schiffman JD, Chun N, Fisher PG, Dahl GV, Ford JM, Eggerding FA. Pediatr Blood Cancer. 2008; 50 (4): 914-6
• Identifying and Preventing High-risk Gastric Cancer Individuals With CDH1 Mutations. Norton JA, Ford JM. Ann Surg. 2008; 247 (4): 715-716
• Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Jensen KC, Mariappan MR, Putcha GV, Husain A, Chun N, Ford JM, Schrijver I, Longacre TA. Am J Surg Pathol. 2008; 32 (7): 1029-37
• Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Rogers WM, Dobo E, Norton JA, Van Dam J, Jeffrey RB, Huntsman DG, Kingham K, Chun N, Ford JM, Longacre TA. Am J Surg Pathol. 2008; 32 (6): 799-809
• Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage. Ghanouni P, Kurian AW, Margolis D, Hartman AR, Mills MA, Plevritis SK, Ford JM, Daniel BL. Breast J. 2007 May-Jun; 13 (3): 281-6
• A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. Ghataorhe P, Kurian AW, Pickart A, Trapane P, Norton JA, Kingham K, Ford JM. Cancer Genet Cytogenet. 2007; 179 (2): 89-92
• Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, Oliveira C, Tischkowitz M, Olschwang S, Gallinger S, Lynch H, Green J, Ford J, Pharoah P, Fernandez B, Huntsman D. JAMA. 2007; 297 (21): 2360-72
• HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ. Proc Natl Acad Sci U S A. 2007; 104 (49): 19482-7
• Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays. Mullins FM, Dietz L, Lay M, Zehnder JL, Ford J, Chun N, Schrijver I. Genet Med. 2007; 9 (11): 752-60
• Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Alli E, Yang JM, Ford JM, Hait WN. Mol Pharmacol. 2007; 71 (5): 1233-40
• A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. Chen X, Zhang J, Lee J, Lin PS, Ford JM, Zheng N, Zhou P. Mol Cell. 2006; 22 (4): 489-99
• Colorectal Cancer Screening Clinical Practice Guidelines. Levin B, Barthel JS, Burt RW, David DS, Ford JM, Giardiello FM, Gruber SB, Halverson AL, Hamilton S, Kohlmann W, Ludwig KA, Lynch PM, Marino C, Martin EW, Mayer RJ, Pasche B, Pirruccello SJ, Rajput A, Rao MS, Shike M, Steinbach G, Terdiman JP, Weinberg D, Winawer SJ. J Natl Compr Canc Netw. 2006; 4 (4): 384-420
• Genetic/familial high-risk assessment: breast and ovarian. Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN. J Natl Compr Canc Netw. 2006; 4 (2): 156-76
• Germ line mutations of mismatch repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Park JG, Kim DW, Hong CW, Nam BH, Shin YK, Hong SH, Kim IJ, Lim SB, Aronson M, Bisgaard ML, Brown GJ, Burn J, Chow E, Conrad P, Douglas F, Dunlop M, Ford J, Greenblatt MS, Heikki J, Heinimann K, Lynch EL, Macrae F, McKinnon WC, Möeslein G, Rossi BM, Rozen P, Schofield L, Vaccaro C, Vasen H, Velthuizen M, Viel A, Wijnen J. Clin Cancer Res. 2006; 12 (11 Pt 1): 3389-93
• Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Suriano G, Yew S, Ferreira P, Senz J, Kaurah P, Ford JM, Longacre TA, Norton JA, Chun N, Young S, Oliveira MJ, Macgillivray B, Rao A, Sears D, Jackson CE, Boyd J, Yee C, Deters C, Pai GS, Hammond LS, McGivern BJ, Medgyesy D, Sartz D, Arun B, Oelschlager BK, Upton MP, Neufeld-Kaiser W, Silva OE, Donenberg TR, Kooby DA, Sharma S, Jonsson BA, Gronberg H, Gallinger S, Seruca R, Lynch H, Huntsman DG. Clin Cancer Res. 2005; 11 (15): 5401-9
• Ductal lavage of fluid-yielding and non-fluid-yielding ducts in BRCA1 and BRCA2 mutation carriers and other women at high inherited breast cancer risk. Kurian AW, Mills MA, Jaffee M, Sigal BM, Chun NM, Kingham KE, Collins LC, Nowels KW, Plevritis SK, Garber JE, Ford JM, Hartman AR. Cancer Epidemiol Biomarkers Prev. 2005; 14 (5): 1082-9
• Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Kurian AW, Hartman AR, Mills MA, Ford JM, Daniel BL, Plevritis SK. Health Expect. 2005; 8 (3): 221-33
• Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI. J Clin Oncol. 2005; 23 (24): 5613-9
• Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP. Int J Radiat Oncol Biol Phys. 2005; 63 (2): 320-3
• Regulation of DNA damage recognition and nucleotide excision repair: another role for p53. Ford JM, Mutat Res. 2005; 577 (1-2): 195-202
• Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Hartman AR, Daniel BL, Kurian AW, Mills MA, Nowels KW, Dirbas FM, Kingham KE, Chun NM, Herfkens RJ, Ford JM, Plevritis SK. Cancer. 2004; 100 (3): 479-89
• Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C, Ford J, Poen J, Gibbs IC, Mehta VK, Kee S, Trueblood W, Yang G, Bastidas JA. Int J Radiat Oncol Biol Phys. 2004; 58 (4): 1017-21
• BRCA1 and p53: compensatory roles in DNA repair. Hartman AR, Ford JM. J Mol Med (Berl). 2003; 81 (11): 700-7
• Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Karlsson A, Deb-Basu D, Cherry A, Turner S, Ford J, Felsher DW. Proc Natl Acad Sci U S A. 2003; 100 (17): 9974-9
• Functional characterization of global genomic DNA repair and its implications for cancer. Hanawalt PC, Ford JM, Lloyd DR. Mutat Res. 2003; 544 (2-3): 107-14
• Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. Mehta VK, Cho C, Ford JM, Jambalos C, Poen J, Koong A, Lin A, Bastidas JA, Young H, Dunphy EP, Fisher G. Int J Radiat Oncol Biol Phys. 2003; 55 (1): 132-7
• DNA Damage, Repair, and Diseases. Wiesmüller L, Ford JM, Schiestl RH. J Biomed Biotechnol. 2002; 2 (2): 45
• Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. Mehta VK, Fisher G, Ford JA, Poen JC, Vierra MA, Oberhelman H, Niederhuber J, Bastidas JA. J Gastrointest Surg. 2001 Jan-Feb; 5 (1): 27-35
• Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of Vater: preliminary report. Mehta VK, Fisher GA, Ford JM, Poen JC, Vierra MA, Oberhelman HA, Bastidas AJ. Arch Surg. 2001; 136 (1): 65-9
• Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Mehta VK, Poen JC, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, Fisher GA. Am J Clin Oncol. 2001; 24 (2): 155-9
• Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. Mehta VK, Poen J, Ford J, Edelstein PS, Vierra M, Bastidas AJ, Young H, Fisher G. Dis Colon Rectum. 2001; 44 (1): 52-8
• The p53-regulated cyclin-dependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts. Adimoolam S, Lin CX, Ford JM. J Biol Chem. 2001; 276 (28): 25813-22
• Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Mehta VK, Fisher GA, Ford JM, Oberhelman HA, Vierra MA, Bastidas AJ, Poen JC. Int J Radiat Oncol Biol Phys. 2000; 48 (5): 1483-7
• Decreased UV sensitivity, mismatch repair activity and abnormal cell cycle checkpoints in skin cancer cell lines derived from UVB-irradiated XPA-deficient mice. Ichikawa M, Nakane H, Marra G, Corti C, Jiricny J, Fitch M, Ford JM, Ikejima M, Shimada T, Yoshino M, Takeuchi S, Nakatsu Y, Tanaka K. Mutat Res. 2000; 459 (4): 285-98
• Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53. Lopez CD, Ao Y, Rohde LH, Perez TD, O'Connor DJ, Lu X, Ford JM, Naumovski L. Mol Cell Biol. 2000; 20 (21): 8018-25
• Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells. Bowman KK, Sicard DM, Ford JM, Hanawalt PC. Mol Carcinog. 2000; 29 (1): 17-24
• p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. Smith ML, Ford JM, Hollander MC, Bortnick RA, Amundson SA, Seo YR, Deng CX, Hanawalt PC, Fornace AJ. Mol Cell Biol. 2000; 20 (10): 3705-14
• Chemoradiotherapy in the management of localized tumors of the pancreas. Poen JC, Ford JM, Niederhuber JE. Ann Surg Oncol. 1999 Jan-Feb; 6 (1): 117-22
• Hepatitis B x protein inhibits p53-dependent DNA repair in primary mouse hepatocytes. Prost S, Ford JM, Taylor C, Doig J, Harrison DJ. J Biol Chem. 1998; 273 (50): 33327-32
• Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation. Ford JM, Baron EL, Hanawalt PC. Cancer Res. 1998; 58 (4): 599-603
• Role of DNA excision repair gene defects in the etiology of cancer. Ford JM, Hanawalt PC. Curr Top Microbiol Immunol. 1997: 221 47-70
• Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Ford JM, Eur J Cancer. 1996; 32A (6): 991-1001
• P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Ford JM, Yang JM, Hait WN. Cancer Treat Res. 1996: 87 3-38
• Modulators of multidrug resistance. Preclinical studies. Ford JM, Hematol Oncol Clin North Am. 1995; 9 (2): 337-61
• Preferential repair of ultraviolet light-induced DNA damage in the transcribed strand of the human p53 gene. Ford JM, Lommel L, Hanawalt PC. Mol Carcinog. 1994; 10 (2): 105-9
• Pharmacologic circumvention of multidrug resistance. Ford JM, Hait WN. Cytotechnology. 1993; 12 (1-3): 171-212
• Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice. Ford JM, Yang JM, Hait WN. Cancer Res. 1991; 51 (1): 67-72
• Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers. Ford JM, Hait WN, Matlin SA, Benz CC. Cancer Lett. 1991; 56 (1): 85-94
• Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomers. Benz CC, Keniry MA, Ford JM, Townsend AJ, Cox FW, Palayoor S, Matlin SA, Hait WN, Cowan KH. Mol Pharmacol. 1990; 37 (6): 840-7
• Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN. Cancer Res. 1990; 50 (6): 1748-56
• Pharmacology of drugs that alter multidrug resistance in cancer. Ford JM, Hait WN. Pharmacol Rev. 1990; 42 (3): 155-99
• Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Ford JM, Prozialeck WC, Hait WN. Mol Pharmacol. 1989; 35 (1): 105-15
• Toremifene: pharmacologic and pharmacokinetic basis of reversing multidrug resistance. DeGregorio MW, Ford JM, Benz CC, Wiebe VJ. J Clin Oncol. 1989; 7 (9): 1359-64